Table 3.
Medical treatment and interventions during the follow-up of adult patients with primary intestinal lymphangiectasia
|
Case number
|
Age/sex
|
Albumin
|
Octreotide
|
Tranexamic acid
|
Steroid
|
Sirolimus
|
Everolimus
|
Outcome of treatment
|
Lng mediastinum MRI (reason)
|
Lymphangiography
|
Lymphatic embolization
|
| Periodic injection intravenously | Subcutaneous; Dose; Frequency; Duration | Oral; Dose; Frequency; Duration | Oral; Dose; Frequency; Duration | Oral; Dose; Frequency; Duration | Oral; Dose; Frequency; Duration | No/yes (reason) | No/yes (reason) | No/yes (reason) | |||
| 1 | 30/M | Yes | (5) 100-200 mcg qd-bid for 6 month | (4) 500 mg tid for 3 month | (2) 40 mg tapered for 2 month | (3)-(4) 1-2 mg qd for 6 month | (1) 2.5 mg qd for 2 month | Improvement and observation after stopping medical treatment | |||
| 2 | 70/M | Yes | (1)-(3) 50-100 mcg qd-bid for continuously | (2) 500 mg tid for 3 month | (3) 1 mg qd for 6 month | Octreotide continuously | |||||
| 3 | 63/F | Yes | Unable to treat appropriately due to underlying colon cancer | ||||||||
| 4 | 54/M | Yes | (1) 2-3 mg qd for continuously | Sirolimus continuously | |||||||
| 5 | 28/F | Yes | (1)-(2) 100 mcg qd for 6 month | (2) 1-2 mg qd for continuously | Sirolimus continuously | ||||||
| 6 | 67/F | Yes | (1) 100 mcg bid for 3 month | (2) 250 mg tid for continuously | (2) 2 mg qd for continuously | Tranexamic acid and sirolimus continuously | Yes (pleural effusion) | Yes (pleural effusion) | Yes (pleural effusion) | ||
| 7 | 32/M | Yes | Regular albumin replacement | No | No | No | |||||
| 8 | 65/M | Yes | (1) 1-2 mg qd for continuously | Sirolimus continuously | No | No | No | ||||
| 9 | 41/F | Yes | (1) 40 mg tapered for 4 wk | (2) 1-2 mg qd for 1.5 yr | Improvement and observation after stopping medical treatment | Yes (pleural effusion) | No | No | |||
| 10 | 35/M | Yes | (1)-(2) 50-200 mcg qd-bid for 2 yr | (4) 250 mg tid for 6 month | (3) 30 mg tapered for 1 month | (2)-(4) 1 mg qd for continuously | Sirolimus continuously | Yes (pleural effusion) | Yes (pleural effusion) | No | |
| 11 | 32/M | Yes | (2) 100 mcg qd-bid for continuously | (1)-(2) 1-4 mg qd for continuously | Octreotide and sirolimus continuously | No | No | No | |||
| 12 | 76/F | Yes | (2) 100 mcg qd-bid for continuously | (1) 1 mg qd-bid for 6 month | Octreotide continuously | No | No | No |
bid: Bis in die (two times a day); F: Female; M: Male; tid: Ter in die (three times a day); qd: Quaque die (once a day); qid: Quarter in die (four times a day).